Baricitinib
FDA-approved product (tablet, oral), marketed as Baricitinib, Olumiant.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Rheumatoid arthritis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Janus-associated kinase (jak) inhibitors
- FDA pharmacologic class
- Janus Kinase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Baricitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of Baricitinib and Probenecid in Healthy Participants
NCT01937026 · start 2013-09
Registered record
- Registry ID
- NCT01937026
- Conditions
- Healthy Volunteers
- Interventions
- Baricitinib; Probenecid
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2013-11
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionBaricitinib; ProbenecidPhasePhase 1Registry statusCompletedA Study of Baricitinib and Rifampicin in Healthy Participants
NCT01910311 · start 2013-08
Registered record
- Registry ID
- NCT01910311
- Conditions
- Healthy Volunteers
- Interventions
- Baricitinib; Rifampicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-08
- Completion
- 2013-10
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionBaricitinib; RifampicinPhasePhase 1Registry statusCompletedA Study in Moderate to Severe Rheumatoid Arthritis
NCT01710358 · start 2012-10
Registered record
- Registry ID
- NCT01710358
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab; Baricitinib; Methotrexate; Adalimumab Placebo; Baricitinib Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2015-09
- Enrolment
- 1,307
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRheumatoid ArthritisInterventionAdalimumab; Baricitinib; Methotrexate; Adalimumab Placebo +1 morePhasePhase 3Registry statusCompletedA Study of LY3009104 in Healthy Participants
NCT01536951 · start 2012-02
Registered record
- Registry ID
- NCT01536951
- Conditions
- Healthy Participants
- Interventions
- LY3009104; Placebo; moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2013-05
- Enrolment
- 62
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy ParticipantsInterventionLY3009104; Placebo; moxifloxacinPhasePhase 1Registry statusCompletedDisposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
NCT01299285 · start 2011-02
Registered record
- Registry ID
- NCT01299285
- Conditions
- Healthy Volunteers
- Interventions
- LY3009104
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2011-03
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionLY3009104PhasePhase 1Registry statusCompleted